 Joel Marrs
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 453 | 1.430 |
Why?
| | Antihypertensive Agents | 5 | 2021 | 508 | 1.410 |
Why?
| | Pharmacists | 8 | 2023 | 263 | 1.320 |
Why?
| | Hypertension | 7 | 2021 | 1252 | 1.300 |
Why?
| | Aspirin | 3 | 2015 | 385 | 1.080 |
Why?
| | Text Messaging | 3 | 2025 | 179 | 1.010 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2015 | 475 | 1.010 |
Why?
| | Education, Pharmacy | 6 | 2023 | 133 | 0.890 |
Why?
| | Cardiovascular Diseases | 9 | 2025 | 2087 | 0.890 |
Why?
| | Hypolipidemic Agents | 4 | 2025 | 92 | 0.890 |
Why?
| | Atrial Fibrillation | 2 | 2019 | 383 | 0.790 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2017 | 2526 | 0.780 |
Why?
| | Anticoagulants | 2 | 2019 | 675 | 0.760 |
Why?
| | Thiophenes | 2 | 2015 | 122 | 0.700 |
Why?
| | Stroke | 4 | 2019 | 1154 | 0.690 |
Why?
| | Dyslipidemias | 4 | 2025 | 175 | 0.690 |
Why?
| | Allylamine | 2 | 2012 | 7 | 0.680 |
Why?
| | Internship, Nonmedical | 2 | 2010 | 13 | 0.580 |
Why?
| | Medication Reconciliation | 1 | 2018 | 31 | 0.560 |
Why?
| | Pharmaceutical Services | 2 | 2020 | 87 | 0.460 |
Why?
| | Heart Failure, Diastolic | 1 | 2015 | 23 | 0.450 |
Why?
| | Cholesterol, LDL | 5 | 2019 | 361 | 0.450 |
Why?
| | Kidney Failure, Chronic | 2 | 2011 | 596 | 0.450 |
Why?
| | Ticlopidine | 1 | 2015 | 52 | 0.450 |
Why?
| | Drug-Eluting Stents | 1 | 2015 | 84 | 0.440 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1597 | 0.440 |
Why?
| | Thromboembolism | 1 | 2015 | 118 | 0.440 |
Why?
| | Medically Underserved Area | 1 | 2015 | 96 | 0.430 |
Why?
| | Blood Pressure | 3 | 2016 | 1748 | 0.380 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 1365 | 0.380 |
Why?
| | Piperazines | 1 | 2015 | 354 | 0.380 |
Why?
| | Guideline Adherence | 1 | 2016 | 565 | 0.370 |
Why?
| | Reminder Systems | 2 | 2025 | 174 | 0.370 |
Why?
| | Patient Discharge | 2 | 2018 | 932 | 0.370 |
Why?
| | Urban Population | 1 | 2015 | 485 | 0.360 |
Why?
| | Glucosides | 1 | 2012 | 49 | 0.360 |
Why?
| | Cardiovascular Agents | 2 | 2025 | 156 | 0.360 |
Why?
| | Humans | 45 | 2025 | 141197 | 0.340 |
Why?
| | Anticholesteremic Agents | 2 | 2012 | 155 | 0.340 |
Why?
| | Thrombosis | 1 | 2015 | 399 | 0.340 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 337 | 0.340 |
Why?
| | Spironolactone | 1 | 2010 | 34 | 0.330 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2010 | 56 | 0.320 |
Why?
| | Preceptorship | 1 | 2010 | 68 | 0.310 |
Why?
| | Administration, Oral | 3 | 2019 | 803 | 0.310 |
Why?
| | Professional Role | 3 | 2020 | 168 | 0.300 |
Why?
| | Students, Pharmacy | 1 | 2010 | 105 | 0.290 |
Why?
| | Medication Therapy Management | 2 | 2020 | 79 | 0.280 |
Why?
| | Schools, Pharmacy | 3 | 2021 | 49 | 0.270 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1040 | 0.270 |
Why?
| | Medication Adherence | 3 | 2025 | 513 | 0.270 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 198 | 0.260 |
Why?
| | Benzodiazepines | 1 | 2008 | 156 | 0.260 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 48 | 0.260 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2021 | 101 | 0.250 |
Why?
| | Insurance Coverage | 1 | 2008 | 237 | 0.250 |
Why?
| | Family Practice | 2 | 2010 | 464 | 0.250 |
Why?
| | Renal Dialysis | 1 | 2010 | 457 | 0.240 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 214 | 0.240 |
Why?
| | Certification | 3 | 2013 | 118 | 0.240 |
Why?
| | Hospitalization | 2 | 2015 | 2255 | 0.230 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2008 | 192 | 0.230 |
Why?
| | Aged | 11 | 2025 | 24576 | 0.220 |
Why?
| | Heart Failure | 1 | 2018 | 2088 | 0.220 |
Why?
| | Faculty | 2 | 2017 | 154 | 0.210 |
Why?
| | Poverty | 1 | 2008 | 530 | 0.210 |
Why?
| | Endocrinology | 1 | 2025 | 76 | 0.210 |
Why?
| | Specialization | 3 | 2013 | 130 | 0.190 |
Why?
| | Ambulatory Care | 1 | 2007 | 582 | 0.190 |
Why?
| | Social Identification | 1 | 2023 | 72 | 0.190 |
Why?
| | Middle Aged | 11 | 2025 | 34438 | 0.180 |
Why?
| | Pharmacy | 1 | 2021 | 32 | 0.170 |
Why?
| | Colesevelam Hydrochloride | 2 | 2012 | 7 | 0.170 |
Why?
| | Pharmacy Service, Hospital | 2 | 2013 | 87 | 0.170 |
Why?
| | Cell Phone | 1 | 2021 | 82 | 0.170 |
Why?
| | Secondary Prevention | 3 | 2016 | 241 | 0.160 |
Why?
| | Brain Ischemia | 2 | 2013 | 349 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1074 | 0.150 |
Why?
| | Female | 13 | 2025 | 75522 | 0.150 |
Why?
| | Societies, Pharmaceutical | 3 | 2021 | 21 | 0.140 |
Why?
| | Software | 1 | 2023 | 676 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2021 | 16273 | 0.140 |
Why?
| | Age Factors | 2 | 2016 | 3292 | 0.140 |
Why?
| | Heart Valve Diseases | 1 | 2019 | 153 | 0.140 |
Why?
| | Colorado | 2 | 2023 | 4610 | 0.130 |
Why?
| | 4-Hydroxycoumarins | 1 | 2016 | 4 | 0.130 |
Why?
| | Blood Glucose | 3 | 2012 | 2269 | 0.130 |
Why?
| | Dissociative Disorders | 1 | 2016 | 25 | 0.130 |
Why?
| | Vitamin K | 1 | 2016 | 42 | 0.130 |
Why?
| | Male | 11 | 2025 | 69789 | 0.120 |
Why?
| | Community Participation | 1 | 2017 | 138 | 0.120 |
Why?
| | Cholesterol | 3 | 2019 | 405 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1052 | 0.120 |
Why?
| | Primary Prevention | 2 | 2014 | 202 | 0.120 |
Why?
| | Risk Factors | 5 | 2019 | 10438 | 0.120 |
Why?
| | Patient Transfer | 1 | 2018 | 181 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2015 | 7856 | 0.110 |
Why?
| | Blood Coagulation Disorders | 1 | 2016 | 186 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2016 | 273 | 0.110 |
Why?
| | Adult | 8 | 2025 | 39181 | 0.110 |
Why?
| | Diuretics | 2 | 2011 | 73 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 891 | 0.100 |
Why?
| | United States | 8 | 2025 | 15220 | 0.100 |
Why?
| | Emotional Intelligence | 2 | 2023 | 13 | 0.100 |
Why?
| | Suicide, Attempted | 1 | 2016 | 393 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2019 | 11120 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5200 | 0.100 |
Why?
| | Acute Disease | 1 | 2015 | 1008 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 661 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2012 | 75 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2015 | 404 | 0.090 |
Why?
| | Hyperlipidemias | 1 | 2012 | 125 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 757 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 287 | 0.080 |
Why?
| | Sex Factors | 1 | 2016 | 2059 | 0.080 |
Why?
| | Drug Resistance | 1 | 2010 | 150 | 0.080 |
Why?
| | Universities | 1 | 2013 | 452 | 0.080 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5636 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2010 | 217 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2016 | 1069 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 702 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 7070 | 0.070 |
Why?
| | Advisory Committees | 2 | 2021 | 220 | 0.070 |
Why?
| | Patient-Centered Care | 1 | 2013 | 550 | 0.070 |
Why?
| | Adamantane | 1 | 2007 | 18 | 0.070 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2007 | 14 | 0.070 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 141 | 0.070 |
Why?
| | Emotions | 2 | 2023 | 575 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2007 | 90 | 0.060 |
Why?
| | Eicosapentaenoic Acid | 1 | 2006 | 38 | 0.060 |
Why?
| | Hypertriglyceridemia | 1 | 2006 | 39 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1336 | 0.060 |
Why?
| | Nitriles | 1 | 2007 | 181 | 0.060 |
Why?
| | Docosahexaenoic Acids | 1 | 2006 | 86 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2103 | 0.060 |
Why?
| | Aging | 1 | 2016 | 1893 | 0.060 |
Why?
| | Insurance, Health | 1 | 2008 | 299 | 0.060 |
Why?
| | Risk Assessment | 2 | 2016 | 3490 | 0.060 |
Why?
| | Young Adult | 4 | 2015 | 13673 | 0.060 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2006 | 142 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2009 | 361 | 0.060 |
Why?
| | Triglycerides | 1 | 2006 | 514 | 0.050 |
Why?
| | Animals | 3 | 2012 | 37663 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 610 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 854 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1654 | 0.050 |
Why?
| | Adolescent | 4 | 2015 | 22007 | 0.050 |
Why?
| | Sleep | 1 | 2008 | 877 | 0.040 |
Why?
| | Curriculum | 1 | 2006 | 1033 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 689 | 0.030 |
Why?
| | Annual Reports as Topic | 1 | 2017 | 3 | 0.030 |
Why?
| | Students | 1 | 2023 | 645 | 0.030 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 97 | 0.030 |
Why?
| | Organizational Policy | 1 | 2017 | 83 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1556 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 737 | 0.030 |
Why?
| | Eating | 1 | 2016 | 392 | 0.030 |
Why?
| | Mechanical Thrombolysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Clinical Competence | 2 | 2011 | 1202 | 0.020 |
Why?
| | Adrenergic Antagonists | 1 | 2011 | 6 | 0.020 |
Why?
| | Telephone | 1 | 2013 | 182 | 0.020 |
Why?
| | Renin | 1 | 2011 | 36 | 0.020 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 154 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 38 | 0.020 |
Why?
| | Phytotherapy | 1 | 2011 | 82 | 0.020 |
Why?
| | Drug Utilization | 1 | 2011 | 169 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 172 | 0.020 |
Why?
| | Patient Care Management | 1 | 2010 | 56 | 0.020 |
Why?
| | Hospitals, University | 1 | 2010 | 175 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5799 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7739 | 0.020 |
Why?
| | Patient Readmission | 1 | 2013 | 706 | 0.020 |
Why?
| | Length of Stay | 1 | 2013 | 1254 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1444 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 507 | 0.010 |
Why?
| | Prevalence | 1 | 2013 | 2772 | 0.010 |
Why?
| | Drug Combinations | 1 | 2006 | 358 | 0.010 |
Why?
| | Primary Health Care | 1 | 2015 | 1799 | 0.010 |
Why?
|
|
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|